Matthew Lam is a lecturer in Pharmaceutics and the inventor of Liqui-Pellet technology. He was a clinical hospital pharmacist who obtained an MPharm at King’s College London and trained at the London’s oldest hospital, St Bartholomew's Hospital, before working at Imperial College Healthcare NHS Trust. Matthew later completed his Ph.D. at the University of Sussex in designing a novel oral dosage form. In 2019, Matthew came back to the University of Sussex as a Lecturer in Pharmaceutics until 2022. He is still associated with the University of Sussex as a visiting lecturer due to his significant contribution to research. Currently, he is a lecturer in Pharmaceutics at London Metropolitan University, where he is the module leader for master students as well as undergraduate students and is part of the core knowledge exchange group.
He holds a patent for a novel drug delivery technology aimed at improving drug efficacy and safety along with being cost-effective and applying green technology. He is interested in next generation oral drug delivery system, and his current work is protected in major international territories, which has gained attention from various pharmaceutical companies along with being featured in PharmaTimes magazine. Matthew likes to integrate his clinical insight into his research (patient-centered research). He focuses on drug delivery to patients with dysphagia, which is usually seen in elderly patients, and the improvement of safety of drugs via drug delivery approach.
Matthew designs laboratory projects for students, he delivers lectures and tutorials at undergraduate and postgraduate level.
Specific field of interest includes:
- Liqui-Pellet technology (also known as Liqui-Mass technology)
- Liquisolid technology
- Controlled release formulation
- Analytical chemistry/ pharmaceutical analysis
- Novel approach to increase bioavailability in drugs
- 3-D printed drugs
Matthew is associated with the University of Sussex as a visiting lecturer due to his significant contribution to research.
- Lam M, Ghafourian T, Nokhodchi A. Liqui-pellet: the emerging next-generation oral dosage form which stems from liquisolid concept in combination with pelletization technology. Aaps Pharmscitech. 2019 Aug;20:1-6.
- Lam M, Ghafourian T, Nokhodchi A. Optimising the release rate of naproxen liqui-pellet: a new technology for emerging novel oral dosage form. Drug Delivery and Translational Research. 2020 Feb;10:43-58.
- Kamal MM, Salawi A, Lam M, Nokhodchi A, Abu-Fayyad A, El Sayed KA, Nazzal S. Development and characterization of curcumin-loaded solid self-emulsifying drug delivery system (SEDDS) by spray drying using Soluplus® as solid carrier. Powder technology. 2020 Jun 1;369:137-45.
- Lam M, Ghafourian T, Nokhodchi A. Liquisolid system and liqui-mass system are not the same. AAPS PharmSciTech. 2020 Apr;21:1-3.
- Lam M, Commandeur D, Maniruzzaman M, Tan DK, Nokhodchi A. The crucial effect of water and co-solvent on Liqui-Pellet pharmaceutical performance. Advanced Powder Technology. 2020 May 1;31(5):1903-14.
- Lam M, Nokhodchi A. Factors affecting performance and manufacturability of naproxen Liqui-Pellet. DARU Journal of Pharmaceutical Sciences. 2020 Dec;28:567-79.
- Lam M, Asare-Addo K, Nokhodchi A. Rapid releasing naproxen Liqui-Pellet using effervescent agent and neusilin US2. Iranian Journal of Basic Medical Sciences. 2021 Jan;24(1):108.
- Nashed N, Lam M, Nokhodchi A. A comprehensive overview of extended release oral dosage forms manufactured through hot melt extrusion and its combination with 3D printing. International journal of pharmaceutics. 2021 Mar 1;596:120237.
- Lam M, Asare-Addo K, Nokhodchi A. Liqui-Tablet: the innovative oral dosage form using the newly developed Liqui-Mass technology. AAPS PharmSciTech. 2021 Apr;22:1-1.
- Lam M, Nokhodchi A. Producing High-Dose Liqui-Tablet (Ketoprofen 100 Mg) for Enhanced Drug Release Using Novel Liqui-Mass Technology. Journal of Pharmaceutical Innovation. 2021:1-3.
- Lam M, Nashed N, Nokhodchi A. Liqui-mass technology as a novel tool to produce sustained release liqui-tablet made from liqui-pellets. Pharmaceutics. 2021 Jul 9;13(7):1049.
- Lam M, Nokhodchi A. A Novel Application of an Effervescent Agent in Naproxen Liqui-Pellets for Enhanced Drug Release. DISSOLUTION TECHNOLOGIES. 2022 May 1;29(2):94-101.
- Lam M, Khoshkhat P, Chamani M, Shahsavari S, Dorkoosh FA, Rajabi A, Maniruzzaman M, Nokhodchi A. In-depth multidisciplinary review of the usage, manufacturing, regulations & market of dietary supplements. Journal of Drug Delivery Science and Technology. 2022 Jan 1;67:102985.
- Sadeghi-Ghadi Z, Behjou N, Ebrahimnejad P, Mahkam M, Goli HR, Lam M, Nokhodchi A. Improving antibacterial efficiency of curcumin in magnetic polymeric nanocomposites. Journal of Pharmaceutical Innovation. 2022 Feb 13:1-6.
- Nazem NM, Shokri J, Nourani N, Zangi AR, Lam M, Nokhodchi A, Javadzadeh Y. Combining liquisolid and co-grinding techniques to enhance the dissolution rate of celecoxib. Journal of Pharmaceutical Innovation. 2022 Apr 11:1-0.
- Nashed N, Lam M, Ghafourian T, Pausas L, Jiri M, Majumder M, Nokhodchi A. An Insight into the Impact of Thermal Process on Dissolution Profile and Physical Characteristics of Theophylline Tablets Made through 3D Printing Compared to Conventional Methods. Biomedicines. 2022 Jun 6;10(6):1335.
- Lam M, Nokhodchi A. The Combination of Liqui-Mass System and Pelletization to Improve Pharmaceutical Properties of Hydrochlorothiazide. DISSOLUTION TECHNOLOGIES. 2022 Aug 1;29(3):128-36.
- Masoomzadeh S, Asnaashari S, Masoomzadeh S, Khosroshahi AY, Lam M, Nokhodchi A, Javadzadeh Y. Could new drug delivery systems affect the pharmaceutical effect of Calendula?. NANO. 2022 Dec 1.
- Nashed N, Chan S, Lam M, Ghafourian T, Nokhodchi A. Effect of pH, Ionic Strength and Agitation Rate on Dissolution Behaviour of 3D-Printed Tablets, Tablets Prepared from Ground Hot-Melt Extruded Filaments and Physical Mixtures. Biomedicines. 2023 Jan 27;11(2):375.
- Gander C, Shi K, Nokhodchi A, Lam M. A review of the benefits 3D printing brings to patients with neurological diseases. Pharmaceutics. 2023 Mar 9;15(3):892.
Pfizer - £12K
University of Sussex Enterprise for Liqui-Pellet technology - £40K
University of Sussex commercial support - £16K
Matthew has worked closely with the Sussex Innovation Centre on strategic engagement with pharmaceutical companies for potential commercialisation of Liqui-Pellet technology.
He is a visiting lecturer at the University of Sussex and at the University of Bedfordshire.
He is a PhD external examiner at the University of East Anglia.
International (PCT) patent application no. PCT/GB2019/052065. International publication
no WO 2020/021254 A1.
Dr Matthew Lam
Lecturer in Pharmaceutics and Drug Delivery